- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.05. | Sol-Gel, Beimei sign deal for TWYNEO commercialisation | ||
| 16.05. | Scorpius announces validation of microbial facilities | ||
| 15.05. | FogPharma and ARTBIO collaborate to co-develop new cancer therapies | ||
| 14.05. | PharmaLogic launches new radiopharmaceutical facility in New York, US | ||
| 10.05. | Aardvark Therapeutics secures $85m in Series C funding round | ||
| 09.05. | IMA Life to build new pharma freeze-drying equipment production site | ||
| 08.05. | ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal | ||
| 07.05. | OverT Bio secures $16m in seed funding for cell therapy development | ||
| 06.05. | FDA accepts BLA for BMS' subcutaneous nivolumab to treat solid tumours | ||
| 03.05. | Latus Bio secures $54m for CNS gene therapy development | ||
| 02.05. | Celltrion secures new public tenders for two biosimilars in Peru | ||
| 01.05. | Scenic Biotech, Bristol Myers Squibb to develop new drug targets | ||
| 30.04. | Genmab and Pfizer's TIVDAK sBLA secures full FDA approval | ||
| 29.04. | FDA approves Ractigen Therapeutics' RAG-01 IND for bladder cancer | ||
| 26.04. | PRISM, ONO to co-create development candidate for oncology target | ||
| 25.04. | US FDA accepts sBLA for GSK's Jemperli for broader endometrial cancer use | ||
| 24.04. | OSR Holdings, SillaJen sign MoU to pursue drug development | ||
| 23.04. | BMS to boost CAR T cell therapy production with Cellares deal | ||
| 22.04. | Merck's PREVYMIS gets Health Canada's approval for CMV disease prevention | ||
| 19.04. | SK pharmteco signs agreement to manufacture Ferring's ADSTILADRIN | ||
| 18.04. | Biocon signs licensing and supply deal for diabetes drug in Brazil | ||
| 17.04. | Orladeyo gains approval in Brazil for HAE prevention | ||
| 16.04. | Telix Pharmaceuticals secures FDA fast track status for TLX101-CDx | ||
| 15.04. | Immuno-oncology company Portage Biotech to evaluate strategic alternatives | ||
| 12.04. | NICE recommends Novartis' CAR-T therapy for leukaemia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
